A New Kind of Diabetes Drug

Both Bristol-Myers Squibb and GlaxoSmithKline are developing new drugs that block the re-absorption of excess glucose by the kidneys, allowing it to be excreted by the body instead.

The new drugs, called sodium glucose uptake transporter 2 inhibitors (SGLT-2), go by the names of dapagliflozin and sergliflozin, respectively. A few preliminary studies have shown that they led to improved glucose levels in patients.

* * *

Source: ADA

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload CAPTCHA.